Nirmatrelvir-Ritonavir Does Not Speed Up Alleviation of COVID-19 Symptoms
By Elana Gotkine HealthDay Reporter
FRIDAY, April 5, 2024 -- For patients with confirmed COVID-19, nirmatrelvir-ritonavir is not associated with a shorter time to sustained alleviation of symptoms than placebo, according to a study published in the April 4 issue of the New England Journal of Medicine.
Jennifer Hammond, Ph.D., from Global Product Development at Pfizer in Collegeville, Pennsylvania, and colleagues randomly assigned adults with confirmed COVID-19 with symptom onset in the past five days to receive nirmatrelvir-ritonavir or placebo every 12 hours for five days (654 and 634 participants, respectively). From day 1 through day 28, participants logged the presence and severity of prespecified COVID-19 signs and symptoms daily.
The researchers found that the median time to alleviation of all targeted signs and symptoms of COVID-19 was 12 and 13 days in the nirmatrelvir-ritonavir and placebo groups, respectively. Five and 10 participants in the nirmatrelvir-ritonavir and placebo groups, respectively, were hospitalized for COVID-19 or died from any cause (difference, −0.8 percentage points; 95 percent confidence interval, −2.0 to 0.4). The percentage of participants with adverse events was 25.8 and 24.1 percent for nirmatrelvir-ritonavir and placebo, respectively.
"Nirmatrelvir-ritonavir was not associated with a significantly shorter time to sustained alleviation of COVID-19 symptoms than placebo, and the usefulness of nirmatrelvir-ritonavir in patients who are not at high risk for severe COVID-19 has not been established," the authors write.
The study was funded by Pfizer.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Further Support and Information on COVID-19
Read this next
No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes
MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...
Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season
WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for...
Global Life Expectancy, Disease Burden Set to Keep Improving
WEDNESDAY, May 22, 2024 -- Life expectancy and age-standardized disease burden are expected to continue improving between 2022 and 2050, according to the Global Burden of Disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.